دورية أكاديمية
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world: The retrospective IMAGE study
| العنوان: | Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world: The retrospective IMAGE study |
|---|---|
| المؤلفون: | Decaux, Olivier, Fontan, Jean, Perrot, Aurore, Karlin, Lionel, Touzeau, Cyrille, Schulmann, Samantha, Manier, Salomon, Belhadj, Karim, Trebouet, Adrien, Zunic, Patricia, de Colella, Jean Marc Schiano, Castel, Brice, van de Wyngaert, Zoé, Pica, Gian Matteo, Tiab, Mourad, Kuhnowski, Frederique, Bouketouche, Malek, Rigaudeau, Sophia, Benramdane, Riad, Tekle, Christina, Lafore, Radhia, Gaucher, Marianne, Corre, Jill, Leleu, Xavier |
| المساهمون: | Microenvironment and B-cells: Immunopathology,Cell Differentiation, and Cancer (MOBIDIC), Université de Rennes (UR)-Etablissement français du sang Rennes (EFS Bretagne)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Etablissement français du sang Rennes (EFS Bretagne), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Toulouse (UT), Centre Hospitalier Lyon Sud CHU - HCL (CHLS), Hospices Civils de Lyon (HCL), Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Hôpital Claude Huriez Lille, Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), CHU Henri Mondor Créteil, Groupe Hospitalier Bretagne Sud (GHBS), CHU Saint-Pierre, Institut Paoli-Calmettes (IPC), Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre Hospitalier de Bigorre Tarbes, Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Saint-Antoine AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Métropole Savoie Chambéry, Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée), Institut Curie Paris, Centre hospitalier de Saint-Quentin, Centre Hospitalier de Versailles André Mignot (CHV), Université Paris Diderot - Paris 7 (UPD7), Centre Hospitalier René Dubos Pontoise, Sanofi US, Sanofi Gentilly (Sanofi Gentilly), Service Hématologie - IUCT-Oncopole CHU Toulouse, Pôle Biologie CHU Toulouse, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle IUCT CHU Toulouse, Laboratoire de génomique du myélome IUCT Oncopole, Toulouse, Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC Poitiers – Centre d'investigation clinique de Poitiers (CIC 1402), Université de Poitiers = University of Poitiers (UP)-Centre hospitalier universitaire de Poitiers = Poitiers University Hospital (CHU de Poitiers La Milétrie )-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Ischémie reperfusion, métabolisme et inflammation stérile en transplantation U 1313 (IRMETIST Poitiers ), Université de Poitiers = University of Poitiers (UP)-Institut National de la Santé et de la Recherche Médicale (INSERM), The IMAGE study was sponsored by Sanofi. |
| المصدر: | ISSN: 0902-4441. |
| بيانات النشر: | HAL CCSD Wiley |
| سنة النشر: | 2024 |
| مصطلحات موضوعية: | dexamethasone, isatuximab, multiple myeloma, pomalidomide, real‐world, [SDV.CAN]Life Sciences [q-bio]/Cancer |
| الوصف: | International audience ; BACKGROUND: IMAGE is a retrospective cohort study of patients enrolled in early access programs (EAPs) in France with relapsed/refractory multiple myeloma (RRMM) receiving isatuximab with pomalidomide and dexamethasone (Isa-Pd). METHODS: Patients aged ≥18 years with RRMM who received ≥1 dose of Isa under the EAPs between July 29, 2019 and August 30, 2020 were included. Effectiveness endpoints included progression-free survival (PFS) and response rates. Verbatim terms for adverse events (AEs) were coded using the Medical Dictionary for Regulatory Activities and not graded for severity. RESULTS: A total of 294 and 299 patients were included in the effectiveness and safety populations, respectively. IMAGE included patients who received one prior line of treatment (10.2%) and were daratumumab-refractory (19.1%). At median follow-up of 14.2 months, median PFS in the effectiveness population was 12.4 months (95% CI 9.0-15.0). Overall response and very good partial response rates were 46.3% and 27.9%, respectively. Subgroup analyses reflected similar results. In the safety population, 26.4% of patients reported at least one AE; the most common any-grade AE was neutropenia (9.4%). CONCLUSION: IMAGE demonstrated Isa-Pd had meaningful effectiveness in median PFS and depth of response and no new safety signals in a real-world context, consistent with clinical trial results. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/38712850; hal-04616020; https://hal.science/hal-04616020Test; PUBMED: 38712850 |
| DOI: | 10.1111/ejh.14225 |
| الإتاحة: | https://doi.org/10.1111/ejh.14225Test https://hal.science/hal-04616020Test |
| حقوق: | http://creativecommons.org/licenses/by-ncTest/ |
| رقم الانضمام: | edsbas.BDFADC3A |
| قاعدة البيانات: | BASE |
| DOI: | 10.1111/ejh.14225 |
|---|